A Budget Impact Analysis To Estimate The Cost Savings from Alectinib on Patients With Anaplastic Lymphoma Kinase (ALK) Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2134
https://www.valueinhealthjournal.com/article/S1098-3015(16)33500-8/fulltext
Title :
A Budget Impact Analysis To Estimate The Cost Savings from Alectinib on Patients With Anaplastic Lymphoma Kinase (ALK) Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Crizotinib
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33500-8&doi=10.1016/j.jval.2016.09.2134
First page :
A719
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2022